Kymera Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KYMR research report →
Range $115 – $180
Price Chart
About the company
Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins.
- CEO
- Nello Mainolfi
- IPO
- 2020
- Employees
- 273
- HQ
- Watertown, MA, US
Get TickerSpark's AI analysis on KYMR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $9.84B
- P/E
- -33.37
- PEG
- 9.69
- P/S
- 101.16
- P/B
- 7.51
- EV/EBITDA
- -29.43
- Div Yield
- 0.00%
- Gross Margin
- 174.52%
- Op Margin
- -396.08%
- Net Margin
- -341.87%
- ROE
- -22.39%
- ROIC
- -23.94%
Latest fiscal year · YoY change
- Revenue
- $39.20M-16.7%
- Gross Profit
- $39.20M-16.7%
- Op Income
- $-349,400,000
- Net Income
- $-311,400,000-39.1%
- EPS
- $-3.69-23.8%
- OCF Growth
- -19.7%
- FCF Growth
- -13.0%
- 52W High
- $142.92
- 52W Low
- $63.69
- 50D MA
- $117.56
- 200D MA
- $100.37
- Beta
- 2.03
- RSI (14)
- 41
- Avg Volume
- 840.35K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Kymera reported strong Phase I KT-579 IRF5 data, kept KT-621 on track for year-end AD results, and said its cash runway extends into 2029.· October 29, 2026
- KT-579 showed deep target engagement: top MAD cohorts reached median IRF5 degradation above 90%, with 94% in blood at the saturated dose level.
- The IRF5 program also hit the biology Kymera wanted to see, with median ex vivo cytokine reductions of 87% to 94% and 98% median inhibition of interferon beta.
- Safety was described as placebo-like, with no serious adverse events, no discontinuations, and no clinically relevant lab, vital sign, or ECG issues.
- KT-621 remains on schedule for BROADEN 2 Phase IIb AD data by year-end, and 98% of eligible patients entered the 52-week open-label extension.
- Management said cash, cash equivalents and investments were approximately $1.6 million and that this supports runway into 2029, including KT-621 and KT-579 development plans.
Kymera did not recognize collaboration revenue in the third quarter, and it does not expect additional collaboration revenue for the remainder of 2026 because prior deferred revenue from Sanofi and Gilead was fully recognized as of the second quarter. Reported R&D expense was $128.5 million, or $117.6 million excluding about $10.9 million of noncash stock-based compensation, up 8% versus the second quarter of 2026. Reported G&A expense was $18.7 million, or $10.8 million adjusted for about $7.9 million of stock-based compensation, down 14% versus the second quarter of 2026. The company ended September with approximately $1.6 million in cash, cash equivalents and investments and said this provides a runway into 2029. Forward looking: KT-621 Phase IIb AD data are expected by year-end, asthma Phase IIb data are expected in late 2027, KT-579 is planned to enter a lupus Phase Ib study by early next year, and Kymera expects to fund KT-621 Phase III AD and the initial stages of Phase III asthma within its current runway.
Nello Mainolfi framed the quarter as a validation of Kymera’s broader degrader platform, saying the company continues to show “impeccable human translation” across first-in-class programs. His tone was confident and strategic, emphasizing that KT-579 is another example of successfully taking a historically hard-to-drug target into humans with strong biomarker readouts and a clear path into lupus. On KT-621, he reiterated the company’s thesis that an effective oral for type 2 disease could expand treatment use beyond the current injectable-biologic market, and he kept focus on year-end AD data and a planned Phase III path in 2027.
Bruce Jacobs said the company remains financially positioned to execute on multiple milestones. He highlighted third-quarter reported R&D of $128.5 million, adjusted R&D of $117.6 million, reported G&A of $18.7 million, and adjusted G&A of $10.8 million. He also noted there was no collaboration revenue in the quarter and no additional collaboration revenue expected in 2026 because prior deferred revenue was already recognized. Importantly, he said the company ended September with approximately $1.6 million in cash, cash equivalents and investments, which he said supports a runway into 2029 and funds KT-621 and KT-579 development, including the planned lupus Phase Ib study and the initial stages of AD and asthma Phase III work.
Analysts focused on KT-579 dose selection, variability, skin versus blood degradation, and how the data might translate into lupus and beyond. Management said there were no meaningful outliers in degradation, that blood and skin responses were broadly similar, and that the study showed robust target engagement even in low-expression skin tissue. They also said the planned lupus study will enroll both interferon-high and interferon-low patients, will look at biomarker and exploratory clinical readouts, and is not powered for clinical endpoints. On KT-621, questions centered on placebo response, itch, conjunctivitis, and how to compare the readout with dupilumab; management said the study was designed with quality controls to reduce placebo risk and that the upcoming AD data will be disclosed in a way investors can interpret, but they avoided giving more detail before the readout.
The call gave Kymera two clear potential value drivers: KT-621 remains on track for a year-end AD readout, while KT-579 posted a strong first-in-human profile with deep degradation, broad biomarker modulation, and placebo-like safety. Management sounded increasingly confident that the platform can translate from preclinical work to humans, and it sees room to expand both programs into multiple autoimmune and inflammatory indications. The company also said its balance sheet is sufficient to carry multiple clinical programs well into the next few years.
The main near-term risk is that the important KT-621 AD readout has not yet arrived, and management repeatedly declined to pin down exact efficacy expectations beyond saying it should be in the “ballpark” of dupilumab. For KT-579, the lupus study is small and exploratory, and management acknowledged it will be hard to interpret clinical signals because placebo rates in lupus are high and the trial is not powered for clinical endpoints. The company also noted it is withholding some biomarker dose-response detail for competitive reasons, which leaves less visibility on dose selection and the exact threshold needed for clinical benefit.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 80.0%
- Shares Outstanding
- 85.37M
- Float Shares
- 68.26M
of shares held by institutions
295 13F filers
Buy/sell ratio 0.14. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Fmr LLC | 12.57M | ▲ 219.66K |
| Baker Bros. Advisors LP | 8.66M | 0 |
| Avoro Capital Advisors LLC | 7.47M | 0 |
| Price T Rowe Associates Inc | 7.11M | ▲ 1.05M |
| Vanguard Group Inc | 6.27M | ▲ 845.92K |
| T. Rowe Price Investment Management, Inc. | 6.26M | ▲ 792.26K |
| Blackrock, Inc. | 5.83M | ▲ 287.21K |
| Bvf Inc/Il | 3.87M | ▼ 1.63M |
| Wellington Management Group Llp | 3.68M | ▼ 214.66K |
| Vanguard Capital Management LLC | 3.04M | ▲ 111.84K |
| Vanguard Portfolio Management LLC | 2.98M | ▼ 13.67K |
| Atlas Venture Life Science Advisors, LLC | 2.85M | 0 |
Held by 435 ETFs
Biggest fund positions in KYMR by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 1, 26 | Mainolfi Nello | other | 30,000 |
| Oct 1, 26 | Mainolfi Nello | sell | 3,525 |
| Oct 1, 26 | Mainolfi Nello | sell | 5,506 |
| Oct 1, 26 | Mainolfi Nello | sell | 4,876 |
| Oct 1, 26 | Mainolfi Nello | sell | 7,601 |
| Oct 1, 26 | Mainolfi Nello | sell | 8,230 |
| Oct 1, 26 | Mainolfi Nello | sell | 262 |
| Oct 1, 26 | Mainolfi Nello | other | 30,000 |
| Sep 4, 26 | Adams Brian | sell | 1,209 |
| Sep 4, 26 | Adams Brian | sell | 3,025 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our KYMR coverage
Recent articles, reports, and earnings notes.

Lycia Therapeutics Prices Its IPO: A Big Bet on Protein Degradation
Lycia Therapeutics Inc. is set to list on Nasdaq on 2026-10-23, and the company has priced its IPO with 17,640,000 shares offered; the price range was not disclosed. The setup is compelling for investors who want exposure to early-stage biotech, but the story still hinges on clinical execution and platform validation.

Should You Buy the Electra Therapeutics IPO? Here's the Setup
Electra Therapeutics is expected to list on NASDAQ on 2026-09-18 in a $14.00 to $16.00 range. The company is offering 21,666,667 shares under ticker ETRA. The bull case is a first-in-class immune-cell depletion platform; the bear case is a clinical-stage biotech with no revenue and rising losses.
Want a deeper read on KYMR?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Kymera Therapeutics to Announce KT-621 BROADEN2 Phase 2b Atopic Dermatitis Trial Results on November 23, 2026
globenewswire.com · Nov 20
Kymera Therapeutics, Inc. $KYMR Shares Sold by Fifth Third Bancorp
defenseworld.net · Nov 18
Kymera Therapeutics, Inc. (KYMR) Q3 2026 Earnings Call Transcript
seekingalpha.com · Oct 29
Kymera Therapeutics Q3 Earnings Call Highlights
marketbeat.com · Oct 29
Kymera Therapeutics Announces Third Quarter 2026 Financial Results and Reports Positive Results from the KT-579 Phase 1 Healthy Volunteer Trial
globenewswire.com · Oct 29
Kymera Therapeutics to Announce KT-579 Phase 1 Healthy Volunteer Trial Results on October 29, 2026
globenewswire.com · Oct 28
Kymera Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026
globenewswire.com · Oct 22
Can KYMR's Targeted Protein Degradation Pipeline Drive Future Growth?
zacks.com · Oct 19
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.